Search

Author/Creator Maxwell, J.

3. Biochemical characterization of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers. (October 2022)

Authors:
Zhang, W.; Gong, S.; Cottrell, K.; Briggs, K.; Tonini, M.; Gu, L.; Whittington, D.; Yuan, H.; Gotur, D.; Jahic, H.; Huang, A.; Maxwell, J.; Mallender, W.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S26
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Characterizing mechanisms of resistance to BRAF and MEK inhibitors in cancers with Class 2 BRAF mutations: uncovering novel therapeutic opportunities. (October 2022)

Authors:
Riaud, M.; Biondini, M.; Cianfarano, E.; Rousselle, E.; Maxwell, J.; Soria-Bretones, I.; Tai, P.; Wang, H.; Siegel, P.M.; Cescon, D.W.; Spreafico, A.; Rose, A.A.N.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S63
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis. Issue 8 (28th July 2015)

Authors:
Jani, Meghna; Chinoy, Hector; Warren, Richard B.; Griffiths, Christopher E. M.; Plant, Darren; Fu, Bo; Morgan, Ann W.; Wilson, Anthony G.; Isaacs, John D.; Hyrich, KimmeL.; Barton, Anne; on behalf of the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators; Prouse...
Journal:
Arthritis & rheumatology
Issue:
Volume 67:Issue 8(2015)
Page Start:
2011
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗